Vangelis D Karalis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9579338/publications.pdf

Version: 2024-02-01

77 1,131 19 27
papers citations h-index g-index

78 78 78 1211
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA. Pharmaceutical Research, 2012, 29, 1066-1077.	3.5	60
2	Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability. Pharmaceutical Research, 2008, 25, 1956-1962.	3.5	53
3	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. American Journal of Medicine, 2022, 135, 32-38.	1.5	41
4	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells, 2021, 10, 1942.	4.1	38
5	Michaelis-Menten Kinetics under Spatially Constrained Conditions: Application to Mibefradil Pharmacokinetics. Biophysical Journal, 2004, 87, 1498-1506.	0.5	35
6	Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties. European Journal of Pharmaceutical Sciences, 2005, 26, 54-61.	4.0	33
7	Novel Scaled Average Bioequivalence Limits Based on GMR and Variability Considerations. Pharmaceutical Research, 2004, 21, 1933-1942.	3.5	32
8	Quantitative structure–pharmacokinetic relationships for disposition parameters of cephalosporins. European Journal of Pharmaceutical Sciences, 2003, 20, 115-123.	4.0	30
9	3D-Printed Oral Dosage Forms: Mechanical Properties, Computational Approaches and Applications. Pharmaceutics, 2021, 13, 1401.	4.5	30
10	Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review. Journal of Pharmaceutical Sciences, 2013, 102, 3018-3036.	3.3	28
11	Novel Scaled Bioequivalence Limits with Leveling-off Properties. Pharmaceutical Research, 2006, 23, 2657-2664.	3.5	27
12	The heterogeneous course of drug transit through the body. Trends in Pharmacological Sciences, 2004, 25, 140-146.	8.7	26
13	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines, 2021, 9, 712.	4.4	25
14	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. Life, 2021, 11, 1077.	2.4	25
15	Pharmacodynamic considerations in bioequivalence assessment: comparison of novel and existing metrics. European Journal of Pharmaceutical Sciences, 2003, 19, 45-56.	4.0	24
16	A non-binary biopharmaceutical classification of drugs: The ABΓ system. International Journal of Pharmaceutics, 2014, 464, 85-90.	5.2	23
17	Generic Products of Antiepileptic Drugs: A Perspective on Bioequivalence, Bioavailability, and Formulation Switches Using Monte Carlo Simulations. CNS Drugs, 2014, 28, 69-77.	5.9	21
18	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 2022, 10, 338.	3.2	21

#	Article	IF	Citations
19	On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline. European Journal of Pharmaceutical Sciences, 2011, 44, 497-505.	4.0	20
20	Safety and Pharmacokinetics of Oseltamivir for Prophylaxis of Neonates Exposed to Influenza H1N1. Pediatric Infectious Disease Journal, 2012, 31, 527-529.	2.0	20
21	Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers. European Journal of Pharmaceutical Sciences, 2015, 80, 33-42.	4.0	20
22	Fractal volume of drug distribution: it scales proportionally to body mass. Pharmaceutical Research, 2001, 18, 1056-1060.	3.5	19
23	Drug disposition viewed in terms of the fractal volume of distribution. Pharmaceutical Research, 2002, 19, 697-704.	3.5	19
24	Hematocrit effect on dried blood spots in adults: a computational study and theoretical considerations. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 325-333.	1.2	19
25	Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens. Xenobiotica, 2021, 51, 643-656.	1.1	19
26	Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. Safety Science, 2020, 129, 104842.	4.9	19
27	Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics. Pharmaceutical Research, 2002, 19, 1827-1834.	3.5	18
28	An Insight into the Properties of a Two-Stage Design in Bioequivalence Studies. Pharmaceutical Research, 2013, 30, 1824-1835.	3.5	17
29	Comparison of neutralizing antibody responses against <scp>SARSâ€CoV</scp> â€2 in healthy volunteers who received the <scp>BNT162b2 mRNA</scp> or the <scp>AZD1222</scp> vaccine: Should the second <scp>AZD1222</scp> vaccine dose be given earlier?. American Journal of Hematology, 2021, 96, E321-E324.	4.1	17
30	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	2.7	17
31	Current regulatory approaches of bioequivalence testing. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 929-942.	3.3	16
32	In Vivo Evaluation of the Anti-Inflammatory Activity of Electrospun Micro/Nanofibrous Patches Loaded with Pinus halepensis Bark Extract on Hairless Mice Skin. Materials, 2019, 12, 2596.	2.9	15
33	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. Frontiers in Endocrinology, 2022, 13, 840668.	3.5	15
34	Examining the Role of Metabolites in Bioequivalence Assessment. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 198.	2.1	14
35	Quantitative assessment of the switchability of generic products. European Journal of Pharmaceutical Sciences, 2013, 50, 476-483.	4.0	14
36	A Physiologically Based Approach for the Estimation of Recirculatory Parameters. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 198-205.	2.5	13

#	Article	IF	Citations
37	Do we need to adopt antifungal stewardship programmes?. European Journal of Hospital Pharmacy, 2020, 27, 14-18.	1.1	12
38	Distinct neutralization profile of spike variants by antibodies induced upon <scp>SARSâ€CoV</scp> â€2 infection or vaccination. American Journal of Hematology, 2022, 97, E3.	4.1	12
39	On the statistical model of the two-stage designs in bioequivalence assessment. Journal of Pharmacy and Pharmacology, 2013, 66, 48-52.	2.4	11
40	Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers. Biopharmaceutics and Drug Disposition, 2017, 38, 407-419.	1.9	11
41	On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches. Pulmonary Pharmacology and Therapeutics, 2018, 48, 168-178.	2.6	10
42	Probing the release of the chronobiotic hormone melatonin from hybrid calcium alginate hydrogel beads. Acta Pharmaceutica, 2020, 70, 527-538.	2.0	10
43	Management of Acute Radiodermatitis in Non-Melanoma Skin Cancer Patients Using Electrospun Nanofibrous Patches Loaded with Pinus halepensis Bark Extract. Cancers, 2021, 13, 2596.	3.7	10
44	Third dose of the <scp>BNT162b2</scp> vaccine results in very high levels of neutralizing antibodies against <scp>SARSâ€CoV</scp> â€2: Results of a prospective study in 150 health professionals in Greece. American Journal of Hematology, 2022, 97, .	4.1	10
45	From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework. Drug Research, 2016, 66, 1-6.	1.7	9
46	Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXPâ€3174. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 193-202.	2.5	9
47	Correlation between Acinetobacter baumannii Resistance and Hospital Use of Meropenem, Cefepime, and Ciprofloxacin: Time Series Analysis and Dynamic Regression Models. Pathogens, 2021, 10, 480.	2.8	9
48	Novel methods to assess bioequivalence. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 79-88.	3.3	8
49	In vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I) Drug Research, 2017, 67, 447-450.	1.7	8
50	Laparoscopic total extraperitoneal inguinal hernia repair. Medicine (United States), 2018, 97, e13974.	1.0	8
51	Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite. European Journal of Pharmaceutical Sciences, 2019, 128, 18-26.	4.0	8
52	Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. European Journal of Pharmaceutical Sciences, 2020, 153, 105498.	4.0	8
53	Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: Focus on human exposure to drugs. European Journal of Pharmaceutical Sciences, 2009, 38, 55-63.	4.0	7
54	In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II). Drug Research, 2017, 67, 653-660.	1.7	7

#	Article	IF	CITATIONS
55	On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. Xenobiotica, 2019, 49, 446-456.	1.1	7
56	Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. Xenobiotica, 2020, 50, 1090-1100.	1,1	7
57	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	3.2	7
58	The role of the upper sample size limit in two-stage bioequivalence designs. International Journal of Pharmaceutics, 2013, 456, 87-94.	5.2	6
59	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. Xenobiotica, 2021, 51, 127-138.	1.1	6
60	Association of Antibiotic Use with the Resistance Epidemiology of Pseudomonas aeruginosa in a Hospital Setting: A Four-Year Retrospective Time Series Analysis. Scientia Pharmaceutica, 2021, 89, 13.	2.0	5
61	An In Vitro–In Vivo Simulation Approach for the Prediction of Bioequivalence. Materials, 2021, 14, 555.	2.9	5
62	Interplay between baroreflex sensitivity, obesity and related cardiometabolic risk factors (Review). Experimental and Therapeutic Medicine, 2021, 23, 67.	1.8	5
63	Paediatric Medicines: Regulatory and Scientific Issues. Drug Research, 2017, 67, 377-384.	1.7	3
64	A retrospective study on the evaluation of the symptoms, medications and improvement of the quality of life of patients undergoing robotic surgery for gastroesophageal reflux disease. Experimental and Therapeutic Medicine, 2020, 21, 174.	1.8	3
65	Exploring the Relationships Between Scaled Bioequivalence Limits and Within-Subject Variability. Journal of Pharmaceutical Sciences, 2013, 102, 297-301.	3.3	2
66	Ropivacaine, Interleukin-6 and Tumor Necrosis Factor Alpha Plasma Levels during Intermittent Epidural and Continuous Wound Infusion of Ropivacaine for Analgesia after Hysterectomy or Myomectomy: An Observational Study. Pharmacology, 2016, 98, 294-298.	2.2	2
67	Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 451-458.	1.6	1
68	Validation of population pharmacokinetic models: a comparison of internal and external validation approaches for hydrochlorothiazide. Xenobiotica, 2021, 51, 1372-1388.	1.1	1
69	The Pharmacokinetics of Levetiracetam in Critically III Adult Patients: An Intensive Care Unit Clinical Study. Applied Sciences (Switzerland), 2022, 12, 1208.	2.5	1
70	Bioequivalence studies in Europe before and after 2010. Clinical Research and Regulatory Affairs, 2015, 32, 9-21.	2.1	0
71	Modeling and Simulation in Bioequivalence. Interdisciplinary Applied Mathematics, 2016, , 227-254.	0.3	0
72	Generic drugs- do they offer the same safety and efficacy as originator medicines? -perceptions and attitudes of final year pharmacy students in greece. Value in Health, 2016, 19, A461.	0.3	0

#	Article	IF	CITATIONS
73	Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Osteoporosis International, 2021, 32, 2313-2321.	3.1	O
74	4CPS-077â€Do we need to adopt antifungal stewardship programmes?. , 2018, , .		0
75	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Blood, 2021, 138, 4202-4202.	1.4	O
76	Quantifying the effect of in-hospital antimicrobial use on the development of colistin-resistant <i>Acinetobacter baumannii</i> strains: a time series analysis. European Journal of Hospital Pharmacy, 2022, 29, 66-71.	1.1	0
77	On the Association between Gastrointestinal Symptoms and Extragastric Manifestations. Gastroenterology Research and Practice, 2022, 2022, 1-10.	1.5	0